BRPI0607523A2 - compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos - Google Patents

compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos

Info

Publication number
BRPI0607523A2
BRPI0607523A2 BRPI0607523-1A BRPI0607523A BRPI0607523A2 BR PI0607523 A2 BRPI0607523 A2 BR PI0607523A2 BR PI0607523 A BRPI0607523 A BR PI0607523A BR PI0607523 A2 BRPI0607523 A2 BR PI0607523A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
medicaments
preparation
pharmaceutical compositions
Prior art date
Application number
BRPI0607523-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of BRPI0607523A2 publication Critical patent/BRPI0607523A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0607523-1A 2005-03-02 2006-03-02 compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos BRPI0607523A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
PCT/US2006/007143 WO2006093993A1 (en) 2005-03-02 2006-03-02 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Publications (1)

Publication Number Publication Date
BRPI0607523A2 true BRPI0607523A2 (pt) 2009-09-08

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607523-1A BRPI0607523A2 (pt) 2005-03-02 2006-03-02 compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos

Country Status (22)

Country Link
US (1) US7875599B2 (sl)
EP (2) EP2206719B1 (sl)
JP (2) JP5130453B2 (sl)
KR (1) KR101380959B1 (sl)
CN (2) CN101155823A (sl)
AT (1) ATE482969T1 (sl)
AU (1) AU2006218711B2 (sl)
BR (1) BRPI0607523A2 (sl)
CA (1) CA2599953C (sl)
DE (1) DE602006017175D1 (sl)
DK (2) DK1853619T3 (sl)
EA (1) EA019560B1 (sl)
ES (2) ES2528055T3 (sl)
HK (1) HK1115387A1 (sl)
IL (3) IL185608A (sl)
MX (1) MX2007010593A (sl)
NZ (1) NZ561571A (sl)
PL (2) PL1853619T3 (sl)
PT (2) PT2206719E (sl)
SI (2) SI1853619T1 (sl)
WO (1) WO2006093993A1 (sl)
ZA (1) ZA200708106B (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
US7875599B2 (en) 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
WO2010062506A2 (en) * 2008-10-28 2010-06-03 Lead Therapeutics, Inc. Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
US20110312916A1 (en) * 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
DK2445903T3 (da) 2009-06-26 2014-06-23 Novartis Ag 1,3-Disubstituerede imidazolidin-2-on-derivater som CYP17-inhibitorer
CA2770092A1 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
AU2010319697B2 (en) * 2009-11-13 2016-05-19 Tokai Pharmaceuticals, Inc. Mammalian metabolites of steroids
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
RU2013132766A (ru) * 2010-12-16 2015-01-27 Байомарин Фармасьютикал Инк. Ингибиторы cyp11b, cyp17 и/или cyp21
CN103649073B (zh) 2011-04-28 2016-04-13 诺瓦提斯公司 17α-羟化酶/C17,20-裂合酶抑制剂
AU2012284053A1 (en) * 2011-07-18 2014-01-23 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
US9884067B2 (en) * 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CA2908577C (en) * 2013-04-04 2022-05-31 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
US11390645B2 (en) 2016-08-08 2022-07-19 Industriale Chimica S.R.L. Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
WO2019160890A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (sl) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2005014023A1 (en) 2003-07-29 2005-02-17 Dompe' Pha.R.Ma S.P.A. Pharmaceutical combination of g-csf and plgf useful for blood stem cell
US7875599B2 (en) 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity

Also Published As

Publication number Publication date
EP1853619A1 (en) 2007-11-14
KR101380959B1 (ko) 2014-04-04
EA019560B1 (ru) 2014-04-30
WO2006093993A1 (en) 2006-09-08
IL210480A0 (en) 2011-03-31
DK1853619T3 (da) 2011-01-10
EP1853619A4 (en) 2009-08-26
SI2206719T1 (sl) 2015-03-31
AU2006218711A2 (en) 2006-09-08
US7875599B2 (en) 2011-01-25
JP2008536807A (ja) 2008-09-11
EP2206719A3 (en) 2011-01-05
EP2206719B1 (en) 2014-10-22
DK2206719T3 (en) 2015-01-26
KR20070120119A (ko) 2007-12-21
PL1853619T3 (pl) 2011-03-31
ATE482969T1 (de) 2010-10-15
CN101155823A (zh) 2008-04-02
SI1853619T1 (sl) 2011-01-31
CN103349664A (zh) 2013-10-16
ES2353413T3 (es) 2011-03-01
DE602006017175D1 (de) 2010-11-11
PL2206719T3 (pl) 2015-03-31
CA2599953A1 (en) 2006-09-08
ES2528055T3 (es) 2015-02-03
EA200701872A1 (ru) 2008-06-30
IL210478A0 (en) 2011-03-31
JP2012255026A (ja) 2012-12-27
JP5613206B2 (ja) 2014-10-22
AU2006218711A1 (en) 2006-09-08
NZ561571A (en) 2009-09-25
US20080280864A1 (en) 2008-11-13
EP1853619B1 (en) 2010-09-29
PT1853619E (pt) 2011-01-03
JP5130453B2 (ja) 2013-01-30
ZA200708106B (en) 2008-12-31
IL185608A0 (en) 2008-01-06
IL210480A (en) 2015-06-30
EP2206719A2 (en) 2010-07-14
IL185608A (en) 2016-06-30
MX2007010593A (es) 2008-02-20
PT2206719E (pt) 2015-02-05
CA2599953C (en) 2013-08-13
AU2006218711B2 (en) 2010-11-11
HK1115387A1 (sl) 2008-11-28

Similar Documents

Publication Publication Date Title
BRPI0607523A2 (pt) compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos
TW200621762A (en) Novel compounds
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
WO2007087548A3 (en) Chemical compounds
WO2007065808A3 (en) Neuropeptide-2 receptor-agonists
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
AU2003242544A1 (en) New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
WO2006096444A3 (en) Chemical compounds
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
TW200639156A (en) New compounds
WO2008004100A9 (en) Therapeutic compounds
WO2003082867A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
IL188848A (en) A transient receptor antagonist (TRPVI) i, a pharmaceutical preparation containing it for the treatment of related diseases and conditions.
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
UA90039C2 (en) Neuropeptide-2 receptor-agonists
AR048536A1 (es) D-homo-17-cloro-16(17)eno esteroides

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: UNIVERSITY OF MARYLAND (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.